North East and North Cumbria
ICS Formulary
ICS Formulary
10 Musculoskeletal and joint diseases
10-02-02 Skeletal muscle relaxants
| Baclofen |
|
First Choice
|
|
|
unlicensed) are also approved; 36mg in 12ml, and 72mg in 12ml intrathecal injections.
| Cannabis extract Sativex® |
|
Formulary
|
|
 NENC Shared Care Protocol: Sativex (delta-9-tetrahydrocannabinol / cannabidiol) Oromucosal Spray NICE NG144: Cannabis-based medicinal products |
|
| Tizanidine |
|
Formulary
|
|
|
Links
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
- NENC Shared Care Protocol: Sativex (delta-9-tetrahydrocannabinol / cannabidiol) Oromucosal Spray
- NHS England Urgent Clinical Commissioning Policy Statement (170018/P)
- NICE NG144: Cannabis-based medicinal products
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence